Viewing the Eph receptors with a focus on breast cancer heterogeneity

Ilias Nikas, Han Suk Ryu, Stamatios Theocharis

Research output: Contribution to journalShort surveyResearchpeer-review

Abstract

Aberrant expression of different family members of the Eph/ephrin system, which comprises the Eph receptors (Ephs) and their ligands (ephrins), has been implicated in various malignancies including breast cancer. The latter presents as a heterogeneous disease with diverse molecular, morphologic and clinical behavior signatures. This review reflects the existing Eph/ephrin literature while focusing on breast cancer heterogeneity. Hormone positive, HER2 positive and triple negative breast cancer (TNBC) cell lines, xenografts/mutant animal models and patient samples are examined separately as, in humans, they represent entities with differences in prognosis and treatment. EphA2, EphB4 and EphB6 are the members most extensively studied in breast cancer. Existing research points to the potential use of various Eph/ephrin members as biomarkers for assessing prognosis and selecting the most suitable therapeutic strategies in variable clinical scenarios, also for overcoming drug resistance, in the era of breast cancer heterogeneity.

Original languageEnglish
Pages (from-to)160-171
Number of pages12
JournalCancer Letters
Volume434
DOIs
StatePublished - 10 Oct 2018

Fingerprint

Eph Family Receptors
Ephrins
Breast Neoplasms
Triple Negative Breast Neoplasms
Drug Resistance
Heterografts
Animal Models
Biomarkers
Hormones
Ligands
Cell Line
Therapeutics
Research
Neoplasms

Keywords

  • Basal-like breast cancer
  • ER
  • Ephrin
  • HER2
  • Targeted therapy
  • Triple negative breast cancer

Cite this

Nikas, Ilias ; Ryu, Han Suk ; Theocharis, Stamatios. / Viewing the Eph receptors with a focus on breast cancer heterogeneity. In: Cancer Letters. 2018 ; Vol. 434. pp. 160-171.
@article{505e32b41d4c42568ba41cbb24b6d073,
title = "Viewing the Eph receptors with a focus on breast cancer heterogeneity",
abstract = "Aberrant expression of different family members of the Eph/ephrin system, which comprises the Eph receptors (Ephs) and their ligands (ephrins), has been implicated in various malignancies including breast cancer. The latter presents as a heterogeneous disease with diverse molecular, morphologic and clinical behavior signatures. This review reflects the existing Eph/ephrin literature while focusing on breast cancer heterogeneity. Hormone positive, HER2 positive and triple negative breast cancer (TNBC) cell lines, xenografts/mutant animal models and patient samples are examined separately as, in humans, they represent entities with differences in prognosis and treatment. EphA2, EphB4 and EphB6 are the members most extensively studied in breast cancer. Existing research points to the potential use of various Eph/ephrin members as biomarkers for assessing prognosis and selecting the most suitable therapeutic strategies in variable clinical scenarios, also for overcoming drug resistance, in the era of breast cancer heterogeneity.",
keywords = "Basal-like breast cancer, ER, Ephrin, HER2, Targeted therapy, Triple negative breast cancer",
author = "Ilias Nikas and Ryu, {Han Suk} and Stamatios Theocharis",
year = "2018",
month = "10",
day = "10",
doi = "10.1016/j.canlet.2018.07.030",
language = "English",
volume = "434",
pages = "160--171",
journal = "Cancer Letters",
issn = "0304-3835",
publisher = "Elsevier Ireland Ltd",

}

Viewing the Eph receptors with a focus on breast cancer heterogeneity. / Nikas, Ilias; Ryu, Han Suk; Theocharis, Stamatios.

In: Cancer Letters, Vol. 434, 10.10.2018, p. 160-171.

Research output: Contribution to journalShort surveyResearchpeer-review

TY - JOUR

T1 - Viewing the Eph receptors with a focus on breast cancer heterogeneity

AU - Nikas, Ilias

AU - Ryu, Han Suk

AU - Theocharis, Stamatios

PY - 2018/10/10

Y1 - 2018/10/10

N2 - Aberrant expression of different family members of the Eph/ephrin system, which comprises the Eph receptors (Ephs) and their ligands (ephrins), has been implicated in various malignancies including breast cancer. The latter presents as a heterogeneous disease with diverse molecular, morphologic and clinical behavior signatures. This review reflects the existing Eph/ephrin literature while focusing on breast cancer heterogeneity. Hormone positive, HER2 positive and triple negative breast cancer (TNBC) cell lines, xenografts/mutant animal models and patient samples are examined separately as, in humans, they represent entities with differences in prognosis and treatment. EphA2, EphB4 and EphB6 are the members most extensively studied in breast cancer. Existing research points to the potential use of various Eph/ephrin members as biomarkers for assessing prognosis and selecting the most suitable therapeutic strategies in variable clinical scenarios, also for overcoming drug resistance, in the era of breast cancer heterogeneity.

AB - Aberrant expression of different family members of the Eph/ephrin system, which comprises the Eph receptors (Ephs) and their ligands (ephrins), has been implicated in various malignancies including breast cancer. The latter presents as a heterogeneous disease with diverse molecular, morphologic and clinical behavior signatures. This review reflects the existing Eph/ephrin literature while focusing on breast cancer heterogeneity. Hormone positive, HER2 positive and triple negative breast cancer (TNBC) cell lines, xenografts/mutant animal models and patient samples are examined separately as, in humans, they represent entities with differences in prognosis and treatment. EphA2, EphB4 and EphB6 are the members most extensively studied in breast cancer. Existing research points to the potential use of various Eph/ephrin members as biomarkers for assessing prognosis and selecting the most suitable therapeutic strategies in variable clinical scenarios, also for overcoming drug resistance, in the era of breast cancer heterogeneity.

KW - Basal-like breast cancer

KW - ER

KW - Ephrin

KW - HER2

KW - Targeted therapy

KW - Triple negative breast cancer

UR - http://www.scopus.com/inward/record.url?scp=85050507631&partnerID=8YFLogxK

U2 - 10.1016/j.canlet.2018.07.030

DO - 10.1016/j.canlet.2018.07.030

M3 - Short survey

VL - 434

SP - 160

EP - 171

JO - Cancer Letters

JF - Cancer Letters

SN - 0304-3835

ER -